XenoPort Announces Presentations at the American Academy of Neurology Meeting

  XenoPort Announces Presentations at the American Academy of Neurology
  Meeting

Business Wire

SANTA CLARA, Calif. -- March 18, 2013

XenoPort, Inc. (Nasdaq: XNPT) announced today that it will present the
following posters at the 65^th Annual Meeting of the American Academy of
Neurology in San Diego, California:

AP (arbaclofen placarbil)
Spasticity

  *An Ongoing Randomized, Double-Blind, Placebo-Controlled Efficacy and
    Safety Study of Arbaclofen Placarbil in Subjects with Spasticity Due to
    Multiple Sclerosis
    Session Info: Poster Session P03: March 19, 2:00 pm - 6:30 pm PT
    Poster #: P03.267
  *The Burden of Multiple Sclerosis-Related Spasticity on Indirect Costs and
    Requirement for Non-Professional Care: Results of a Cross-Sectional Study
    in the USA
    Session Info: Poster Session P03: March 19, 2:00 pm - 6:30 pm PT
    Poster #: P03.217

  *Impact of Spasticity on Healthcare Resource Utilisation: Results of a
    Cross-Sectional Study in the USA
    Session Info: Poster Session P03: March 19, 2:00 pm - 6:30 pm PT
    Poster #: P03.211

XP1279
Parkinson’s Disease

  *Double-Blind Study of an Actively-Transported Levodopa Prodrug, XP21279,
    in Parkinson Disease
    Session Info: Poster Session P02: March 19, 7:30 am – 12:00 pm PT
    Poster #: P02.075

XP23829
Preclinical and Phase 1 Studies

  *Comparative Gastric Irritation of the Fumaric Acid Esters Dimethyl
    Fumarate (DMF) and XP23829 in Rat and Monkey
    Session Info: Poster Session P01: March 18, 2:00 pm - 6:30 pm PT
    Poster #: P01.159

  *Favorable Metabolism and Pharmacokinetics of Formulations of XP32829, a
    Novel Fumaric Acid Ester, in Healthy Subjects
    Session Info: Poster Session P05: March 20, 2:00 pm – 7:00 pm PT
    Poster #: P05.189

About XenoPort

XenoPort is a biopharmaceutical company focused on developing and
commercializing a portfolio of internally discovered product candidates for
the potential treatment of neurological disorders. Horizant® (gabapentin
enacarbil) Extended Release Tablets  is our first approved product in the
United States. GlaxoSmithKline holds commercialization rights for Horizant in
the United States during a transition period ending on April 30, 2013,
following which XenoPort will be responsible for the further development,
manufacturing and commercialization of Horizant. Regnite® (gabapentin
enacarbil) Extended-Release Tablets is approved and is being marketed in
Japan. Astellas Pharma Inc. holds all development and commercialization rights
for Regnite in Japan and five other Asian countries. XenoPort holds all other
world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product
candidates includes potential treatments for patients with spasticity,
Parkinson's disease, relapsing-remitting multiple sclerosis and/or psoriasis.

To learn more about XenoPort, please visit the web site at www.XenoPort.com.

Horizant, Regnite and XENOPORT are registered trademarks of XenoPort, Inc.

Source code: XNPT2C

Contact:

XenoPort, Inc.
Jackie Cossmon, 408-616-7220
ir@XenoPort.com
 
Press spacebar to pause and continue. Press esc to stop.